ArticleMedical oncology (Northwood, London, England)2014
The relationship between genetic variants of XRCC1 gene and lung cancer susceptibility in Chinese Han population.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Associations between polymorphisms in genes of base excision repair pathway and lung cancer risk.Translational cancer research · 2020Article
- Article
- Impact of polymorphisms of the DNA repair gene XRCC1 and their role in the risk of prostate cancer.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous evidence indicate that genetic variants of X-ray repair cross-complementing group 1 gene (XRCC1) are potentially associated with the development of lung cancer. This study aimed to detect the relationship between the XRCC1 genetic variants and lung cancer susceptibility. A total of 420 lung cancer patients and 425 cancer-free healthy controls were recruited in this case-control study. The genotypes of XRCC1 genetic variants were investigated by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The relationship between the XRCC1 genetic variants and lung cancer susceptibility was determined by the association analyses. We found that the distributions of allelic and genotypic in lung cancer patients were significantly different from those of cancer-free healthy controls. Our data indicated that the XRCC1 c.1161G>A and c.1779C>G genetic variants were significantly associated with the increased susceptibility to lung cancer [for c.1161G>A, AA versus (vs.) GG: odds ratio (OR) 2.59, 95 % confidence interval (95 % CI) 1.59-4.21, χ (2) = 15.17, P < 0.001; A vs. G: OR 1.39, 95 % CI 1.13-1.70, P = 0.002; for c.1779C>G, GG vs. CC: OR 2.51, 95 % CI 1.42-4.44, χ (2) = 10.60, P = 0.001; G vs. C: OR 1.24, 95 % CI 1.00-1.54, χ (2) = 3.98, P = 0.046]. The allele A and genotype AA of c.1161G>A and allele G and genotype GG of c.1779C>G genetic variants may enhance lung cancer susceptibility. Taken together, these findings show that the functional c.1161G>A and c.1779C>G genetic variants of XRCC1 are associated with lung cancer susceptibility in the Chinese Han populations and might be used as molecular markers for evaluating the risk of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.